Public Release: 

New avenue for anti-depressant therapy discovered

University of Turku

IMAGE

IMAGE: The image, taken at the Cell Imaging Core, shows these new born cells in the hippocampus, the region of the brain that controls emotions view more

Credit: Turku Centre for Biotechnology

Finnish researchers have made a ground-breaking discovery revealing new molecular information on how the brain regulates depression and anxiety. They found that a protein called JNK when active, represses the generation of new neurons in the hippocampus. By inhibiting JNK solely in newly generated nerve cells in this region, they were able to alleviate anxiety and depressive behaviour in mice.

The work was led by research director Eleanor Coffey, who works at the Turku Centre for Biotechnology, a joint unit of the University of Turku and Åbo Akademi University.

We identified a new molecule that alleviates anxiety and depressive behaviour in rodents. This previously unknown mechanism brings fresh insight on how the brain works to regulate mood and indicates that inhibitors of JNK, such as the one used here, can provide a new avenue for anti-depressant and anxiolytic drug development, Coffey says.

Depression and anxiety are highly prevalent disorders and represent one of the largest causes of disability worldwide. These results are important as many patients to not respond to current treatments and it has long been recognised that new mechanistic understanding of these disorders would be necessary in order to identify drugs for treatment resistant depression.

Researchers used virus tools to find out where in the brain the JNK inhibitor acted to improve mood. They found out the molecule acts to alleviate anxiety and depression by controlling newly born nerve cells in the hippocampus, a part of the brain that controls emotions and learning.

The next step will be to do further tests in rodents. Researchers will test JNK:s additional benefit to existing anti-depressant drugs.

Although we uncover a new mechanism and a new inhibitor molecule that alleviates depression and anxiety in mice, we need to see if this provides additional benefit to existing drugs. Thus, we will do experiments where we administer this new inhibitor together with commonly used drugs and measure fine behavioral details in the mice, Coffey says.

The inhibitor that researchers used is already in clinical trials for stroke and hearing loss.

Actually many large pharma have over the years developed a range of inhibitors to JNK. However it was not earlier known that JNK regulated emotional behavior, so an important message from this study is that JNK should be considered seriously as a target for novel treatments of anxiety and depression.

###

The work, led by Eleanor Coffey, Research Director at Åbo Akademi University is a collaborative effort between scientists in Finland and the US. The research was funded by the EU-funded Marie Curie Initial Training Network r'BIRTH, by the Academy of Finland, Turku Network in Molecular Biosciences and the National Institute on Aging.

The results are published in the Nature Publishing Group Journal, Molecular Psychiatry. Link to publication: http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2016203a.html

PHOTO https://apps.utu.fi/media/tiedostot/dcx.png: The image, taken at the Cell Imaging Core, shows these new born cells in the hippocampus, the region of the brain that controls emotions.

More information: research director Eleanor Coffey, eleanor.coffey@btk.fi

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.